Although compliance professionals tend to view Corporate Integrity Agreements (“CIAs”) as setting the basic compliance standards, in the area of medical inquiry monitoring, they appear to buck the trend by relying on data analytics. This article explores what these professionals are doing and why.
For many in the compliance community, their time, attention and resources are significantly dedicated to fulfilling the requirements of a corporate integrity agreement (“CIA”). This is to be expected if it’s their company’s CIA, because the consequences for failing to comply are severe, up to and including exclusion from participation in federal health care programs. However, many companies structure their compliance programs around the requirements of someone else’s CIA.
Read the full article in the January 2017 issue of Life Science Compliance Update.